

Genetic causes of optic nerve hypoplasia

Chun-An Chen,^{1,2} Jiani Yin,^{1,2} Richard Alan Lewis,^{1,3} Christian P Schaaf^{1,2}

¹Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA

²Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas, USA

³Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA

Correspondence to

Dr Christian P Schaaf, Department of Molecular and Human Genetics, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Baylor College of Medicine, 1250 Moursund Street, Suite 1325, Houston 77030, Texas, USA; schaaf@bcm.edu

Received 2 March 2017

Accepted 5 April 2017

Published Online First

29 April 2017

ABSTRACT

Optic nerve hypoplasia (ONH) is the most common congenital optic nerve anomaly and a leading cause of blindness in the USA. Although most cases of ONH occur as isolated cases within their respective families, the advancement in molecular diagnostic technology has made us realise that a substantial fraction of cases has identifiable genetic causes, typically de novo mutations. An increasing number of genes has been reported, mutations of which can cause ONH. Many of the genes involved serve as transcription factors, participating in an intricate multistep process critical to eye development and neurogenesis in the neural retina. This review will discuss the respective genes and mutations, human phenotypes, and animal models that have been created to gain a deeper understanding of the disorders. The identification of the underlying gene and mutation provides an important step in diagnosis, medical care and counselling for the affected individuals and their families. We envision that future research will lead to further disease gene identification, but will also teach us about gene–gene and gene–environment interactions relevant to optic nerve development. How much of the functional impairment of the various forms of ONH is a reflection of altered morphogenesis versus neuronal homeostasis will determine the prospect of therapeutic intervention, with the ultimate goal of improving the quality of life of the individuals affected with ONH.

INTRODUCTION

The optic nerve, which is composed of retinal ganglion cell axons and supporting glial cells, transmits visual information from the retina to the brain. Optic nerve hypoplasia (ONH) is a non-progressive congenital abnormality characterised by underdevelopment of the optic nerve. Typically, the anomalous optic nerve head appears pale and small, with a pale or pigmented peripapillary halo or double-ringed sign that is visible with ophthalmoscopy. ONH typically occurs bilaterally (80% of all cases). The severity of visual impairment varies between cases. Some eyes with ONH have no light perception, while others have acceptable levels of functional vision. Severe bilateral ONH can be diagnosed within the first few months of life. Affected patients typically manifest early-onset sensory nystagmus (involuntary, rapid eye movements), followed by strabismus (inability to align the eyes simultaneously) often related to the visual impairment due to defective communication between eye and brain. Individuals with unilateral ONH are often diagnosed at an older age, compared with those with bilateral ONH, due to preserved vision in the one normal eye.

The first recorded case of ONH was documented in 1884 in a small child by Magnus.¹ Magnus noticed

a small, pale optic nerve in a boy with nystagmus and a high degree of amblyopia. However, some researchers considered Briere's report to be the first case in 1877.² He described a 7-year-old girl who was born blind, with no optic disc, but normal choroid and central retinal vessels. Some commentators have suggested, however, that the presence of retinal vessels must imply an entrance and exit for them, and thus, given the instrumentation of the period, the disc(s) may have been missed. The first schematic illustration of optic disc appearance of ONH was done by Schwarz in 1915.³ To date, ONH is the second leading cause of blindness and is the most common congenital optic nerve anomaly in the USA.⁴ The reported prevalences of ONH range from 2 to 17.3 per 100 000,⁵ with a considerable rise in prevalence starting in the 1980s. The cause of this increase remains disputed; however, it may be due to heightened physician awareness and improved observation and thus diagnosis of the disorder. Given that most ONH cases are isolated within their respective families, research into the causal factors of ONH has focused on environmental effects. Many environmental risk factors for ONH have been reported, including maternal alcohol abuse during pregnancy, young maternal age, primiparity, maternal use of recreational drugs, anticonvulsants or antidepressants.⁶ However, familial cases of ONH also exist,^{7,8} suggesting genetic aetiologies. With the recent advancement in molecular diagnostic technology, mutations in an increasing number of genes have been reported to cause ONH.

Although rare, the description of ONH may sometimes be confused with optic atrophy,^{6,9} especially when serial examinations have not been done, and the examiner cannot appreciate whether there has been a progression or degeneration over time. Optic atrophy is a condition in which the optic nerve tissues had developed normally and either are damaged and/or degenerate secondarily.

Although ONH can occur as an isolated finding, it is seen much more frequently as part of a syndrome. ONH is usually accompanied by other anterior segmental defects of the eye (MIM 607108),¹⁰ structural abnormalities of the brain, hypopituitarism (MIM 184429),¹¹ developmental delay/intellectual disability, and autism spectrum disorders.¹² This review will focus on the genetic mutations that are currently known to cause ONH. Herein, we will define ONH broadly as any optic disc that shows decreased neuronal area and small optic nerves, congenitally. The reviews of the more narrowly defined septo-optic dysplasia (SOD), also known as de Morsier syndrome, can be found elsewhere.^{5,6,13}

To date, variants in genes involved in transcription regulation, chromatin remodelling,



CrossMark

To cite: Chen C-A, Yin J, Lewis RA, et al. *J Med Genet* 2017;**54**:441–449.

α -dystroglycan glycosylation, cytoskeleton and scaffolding protein, RNA splicing, and the MAP kinase signalling pathway, have been associated with ONH. In the first part of the review, we will introduce the basic functions of the genes involved, the clinical features of the affected individuals and the animal models used to study the respective disorders. In the second part of the review, we will delineate the common developmental pathway shared by some of the key transcription factors in eye development.

Transcription factors

HESX1

HESX1 homeobox 1 (*HESX1*) encodes a homeobox protein, which plays an important role in normal forebrain development and the early determination and differentiation of the pituitary gland in murine models.¹⁴ Dattani *et al* reported the first genetic mutation in *HESX1* (homozygous p.R160C) in a familial case (siblings from a consanguineous family) of SOD.¹⁵ SOD (MIM 182230) is defined by any combination of (1) ONH, (2) pituitary hypoplasia and (3) midline neuroradiological abnormalities, such as defects in the corpus callosum and septum pellucidum. Although the diagnosis of ONH in the study of Dattani *et al* remained controversial,^{13 16} subsequent novel heterozygous *HESX1* mutations were identified in patients with ONH diagnosed with combined pituitary hormone deficiency¹⁷ or SOD.¹⁸ In addition, *HESX1* constitutive knockout mice (*Hesx1*^{-/-}) show substantial perinatal and postnatal lethality and display variable anterior central nervous system (CNS) defects and pituitary dysplasia. Anophthalmia, microphthalmia, defective olfactory development, and abnormalities in the corpus callosum, hippocampal commissures and septum pellucidum were described in *Hesx1*^{-/-} mice, while the milder phenotype was found at very low frequency in *Hesx1*^{+/-} mice (1%).¹⁵

PAX6

Paired box gene 6 (*PAX6*) encodes a transcription factor that is involved in eye morphogenesis. It was first implicated in human aniridia,¹⁹ but later found to be involved in other eye anomalies, including microphthalmia, cataracts, foveal hypoplasia and ONH (MIM 607108). Although ONH is not common in individuals with *PAX6* mutations, Azuma *et al* reported heterozygous *PAX6* mutations (p.Q205X, p.S292I and p.M381V) in three individuals with ONH, one of whom had intellectual disability. In the same study, they also identified heterozygous *PAX6* mutations (p.Q378R and p.T391A) in two patients with optic nerve agenesis.¹⁰ Hingorani *et al*²⁰ summarised ophthalmologic evaluations in 43 individuals with variable anomalies of the iris, carrying heterozygous mutations in *PAX6*. They reported nystagmus and foveal hypoplasia as the most common clinical findings, present in 41 and 37 individuals, respectively. In comparison, ONH was found in 10 individuals in this cohort, most of whom carried frameshift mutations. Given that *PAX6* is also a master regulator of neurogenesis,²¹ abnormalities other than ocular defects have also been reported, including developmental delay,¹⁰ cognitive impairment, autism, epilepsy and structural brain abnormalities of white matter, mostly the corpus callosum.²²

To date, more than 40 *Pax6* mutant mouse models are available (Mouse Genome Informatics (<http://www.informatics.jax.org/>)), most of which have phenotypes affecting the eyes/vision, the nervous system, craniofacial development, and/or mortality. One of the first characterised *Pax6* mouse models is the *Sey/Sey* (Small eye) mouse. *Sey/Sey* pups are born without both eyes and nasal cavities, manifesting a high prevalence of perinatal

mortality due to breathing problems, associated with the absence of the nose.²³ Later studies showed the homozygous knockout animals also had forebrain defects.²⁴ Heterozygous *Sey/+* mice have milder phenotypes. These mice display microphthalmia, frequently with cataracts, which manifest within a few weeks of age, retinal abnormalities and partial or complete absence of the iris.²⁵ The morphogenesis of the optic nerve is also affected in *Sey/+* mice. The cross sectional area and the myelinated fibre counts of optic nerves are decreased significantly in heterozygous mice, a finding more severe in male than female mice; the mechanism is unclear.²⁶

Similar to the mouse, a *Pax6* mutant rat model, *rSey2* (rat Small eye), shows that homozygotes (*rSey2/rSey2*) do not develop lens and nasal placodes and are perinatal lethal, while heterozygotes (*rSey2/+*) have small eyes.²⁷ Later in life, heterozygotes have impaired prepulse inhibition, altered social interaction and low performance in fear-conditioned memory tests, leading the authors to suggest an autism-like phenotype.²⁸

The pleiotropic role of *PAX6* during development can be appreciated through the detailed investigation of several *Pax6* mutant mouse models. *Pax6* consists of three functional domains: the paired domain (PD), the homeodomain (HD) and the transactivating proline-serine-threonine domain. *Pax6* mutations in different functional domains yield different phenotypes. For example, Haubst *et al* compared the *Pax6*^{4^{Neu}} mutants (HD mutation) and *Pax6*^{4^{Aey}18} mutants (PD mutation), and found out that while the former had only subtle effects on forebrain development, the latter had severe impairment of neurogenesis, cell proliferation and patterning in the developing forebrain.²⁹ The molecular consequences of *Pax6*^{Leca2} and *Pax6*^{Leca4} mutants, which carry point mutations in two different subdomains within the PD domain, also differed greatly. While *Pax6*^{Leca2} mutants increased the number of mitoses in the developing cerebral cortex, *Pax6*^{Leca4} mutants showed the opposite. Moreover, neurogenesis was only affected in *Pax6*^{Leca4}, but not *Pax6*^{Leca2} mutants.³⁰ With more than 400 unique human *PAX6* variants reported to date (Leiden Open Variation Database (http://lsdb.hgu.mrc.ac.uk/home.php?select_db=PAX6)), and considering the diverse clinical phenotypes in human patients, the specific mutation needs to be considered to provide accurate diagnosis, counselling and management.

SOX2

SRY (sex determining region Y)-box 2 (*SOX2*) encodes a transcription factor essential for embryonic development of multiple organs, including brain and eyes.³¹ Heterozygous *SOX2* mutations are the most common genetic cause for bilateral anophthalmia and severe microphthalmia. They account for 10%–20% of all patients with microphthalmia/anophthalmia.^{32–34} Among 235 individuals with congenital hypothalamic-pituitary disorders, Kelberman *et al*¹¹ reported two patients (patient 7; p.G130A and patient 8; p.A191T) with bilateral ONH and nystagmus. They discussed the possible neutral nature of these two *SOX2* variants, given that both were inherited from unaffected fathers, but it should be noted that incomplete penetrance for *SOX2* mutations has been reported elsewhere.³⁵ In the same study, another six patients with microphthalmia/anophthalmia were found to carry de novo *SOX2* mutations, and four out of five, for whom MRI data were available, showed either hypoplastic optic nerves or complete agenesis of the optic nerves. Other phenotypes included structural anomalies of the corpus callosum and hippocampus. Bakrania *et al*³³ reported a female patient (case 2; p.N63fs101X) with unilateral ONH

and cataract, atypical coloboma and esotropia in the other eye. The patient had a thin corpus callosum. Ragge *et al*³⁶ reported two patients (case 6; p.L314fs436X and case 7; p.G23fs85X) with bilateral anophthalmia, attenuated optic nerves without visible chiasm, global developmental delay and malformation of the hippocampus. Jayakody *et al*³⁷ reported a patient (patient 1; p.L97P) with bilateral microphthalmia, left sclerocornea and aphakia. MRI data showed right microphthalmos with a prosthesis in situ, a colobomatous left globe, and small optic nerves and chiasm.

Homozygous knockout of *Sox2* causes embryonal lethality in mice, with the products of conception dying shortly after implantation. Heterozygous knockout mice appear normal, except for decreased male fertility.³⁸ Although heterozygous knockout mice do not seem to recapitulate the human eye phenotypes, *Sox2* hypomorphic/null compound heterozygous adult mice (expressing 40% of *Sox2* compared with wild type) show hypoplasia of optic nerves and chiasmata, with eye phenotypes ranging from mild bilateral microphthalmia to severe anophthalmia,³¹ much like heterozygous patients. The authors argued that the striking similarity between heterozygous patients and compound heterozygous mouse models could be explained by species differences; alternatively, it has been suggested that humans with *SOX2*-related eye phenotypes may indeed be compound heterozygotes, carrying a null allele and a hypomorphic allele that brings the total functional level of *SOX2* down to a range that results in phenotypic expression.³¹

NR2F1

Nuclear receptor subfamily 2 group F member 1 (*NR2F1*) encodes a conserved orphan nuclear receptor, which plays a critical role in cortical patterning, axon guidance, neurogenesis, and eye and optic nerve development.^{39–40} We and others identified heterozygous *NR2F1* mutations in individuals manifesting global developmental delay/intellectual disability and ONH/optic atrophy (Bosch-Boonstra-Schaaf Optic Atrophy syndrome, BBSOAS, MIM 615722).^{39–41–42} The phenotypic spectrum of BBSOAS included hypotonia, seizures, autism, oromotor dysfunction, thinning of the corpus callosum and hearing defects.⁴³ To date, pathogenic *NR2F1* variants have been reported as missense, translation initiation variants, frameshifting indels and whole gene deletions. The missense mutations were enriched in the two functional domains of *NR2F1*: the DNA-binding domain (DBD) and the ligand-binding domain. Notably, patients with missense mutations in the DBD generally had more severe phenotypes compared with those carrying a heterozygous whole gene deletion. Given that *NR2F1* binds to DNA in the form of dimers,⁴⁴ a dominant negative effect may be the cause for this phenomenon. A genotype–phenotype correlation was proposed: patients with severe clinical phenotypes carry *NR2F1* variants that tend to have almost completely blunted transcriptional activity, as assessed by *in vitro* luciferase assay.⁴³

Homozygous knockout *Nr2f1*^{-/-} mice die within the first 2 days after birth due to starvation and dehydration. Defects in the formation of the glossopharyngeal nerve in *Nr2f1*^{-/-} pups have been proposed as the cause,⁴⁵ and this observation may relate to the oromotor dysfunction seen in patients with BBSOAS. Abnormal development of the corpus callosum and the hippocampal commissure also is seen in embryonic *Nr2f1*^{-/-} brains.⁴⁶ Eye-specific double knockout of *Nr2f1* and *Nr2f2*, a paralogue of *Nr2f1*, leads to ocular colobomata, microphthalmia and abnormal optic cups. The expression of several regulatory genes critical for early optic vesicle development, such as *Pax6* and *Otx2*, is

altered in double knockout mice, resulting in abnormal differentiation of the progenitor cells at the optic vesicle.⁴⁰ Although all the patients with BBSOAS identified so far carry heterozygous *NR2F1* variants, a heterozygous knockout (*Nr2f1*^{+/-}) mouse model has not been reported.

OTX2

Orthodenticle homeobox 2 (*OTX2*) encodes a HD-containing transcription factor that plays an important role in forebrain and eye development.⁴⁷ Heterozygous mutations in *OTX2* account for 2%–8% of patients with microphthalmia/anophthalmia,^{48–49} making them the second most common genetic cause of microphthalmia/anophthalmia (after *SOX2*). Using a candidate gene approach, Ragge *et al* first reported *OTX2* variants in 11 affected individuals from eight families in a cohort diagnosed with ocular malformation spectrum defects. All of these eight probands had microphthalmia/anophthalmia. The optic nerves and chiasm were absent or reduced in four out of the six patients who had MRI, CT or ultrasound data available for review.⁵⁰ Later studies showed that 35% of the patients with *OTX2* mutations had ONH, while other eye defects such as coloboma and retinal dystrophies were less common.⁴⁹ In addition to ocular abnormalities, the phenotypic spectrum of *OTX2* mutations included structural and functional abnormalities of the pituitary, global developmental delay, autism, attention-deficit disorder, feeding difficulties, seizures, microcephaly and other structural brain anomalies, affecting the corpus callosum and hippocampus.^{49–51} Incomplete penetrance and variable expressivity have been reported for *OTX2* mutations. In the original study, three out of six families with loss-of-function mutations inherited their variants from a phenotypically normal parent (two parents were constitutive mutation carriers, and one was gonosomal mosaic). Variable expressivity has been documented extensively, including individuals sharing the same variant, even among siblings.⁵⁰ Homozygous knockout mice (*Otx2*^{-/-}) are embryonically lethal and display abnormal development of the forebrain, midbrain and rostral hindbrain.⁴⁷ Heterozygous mice show variable phenotypes, including anencephaly, holoprosencephaly, microphthalmia/anophthalmia, micrognathia/agnathia, and short nose.⁵²

VAX1

Ventral anterior homeobox 1 (*VAX1*) encodes a homeobox transcription factor, which plays an important role in the forebrain and visual system.⁵³ Slavotinek *et al*⁵⁴ identified a homozygous missense *VAX1* variant (p.R152S) in a screen of 70 individuals with microphthalmia/anophthalmia. The affected male patient was born to phenotypically normal, consanguineous parents, who were confirmed as heterozygous carriers of the variant. In addition to microphthalmia, other clinical features included ONH, global developmental delay, hippocampal malformations, agenesis of the pineal gland and corpus callosum, and cleft lip/palate. Homozygous knockout *Vax1*^{-/-} mice are perinatally lethal, and the observed phenotypes bear remarkable similarity to the human patient: optic nerve dysgenesis, coloboma and abnormalities in brain structures (corpus callosum, hippocampus and anterior commissure).⁵³ Heterozygous knockout *Vax1*^{+/-} mice appear normal, except for subfertility.⁵⁵

ATOH7

Atonal homologue BHLH transcription factor 7 (*ATOH7*) encodes a basic helix-loop-helix transcription factor, which is critical for retinal ganglion cell and optic nerve formation.⁵⁶ Khan

et al reported two homozygous *ATOH7* variants (one missense and the other as frameshift variant) in two consanguineous families with isolated microphthalmia. Two affected siblings from the family with frameshift mutations also displayed ONH, corneal opacity and retinal detachment. Co-segregation of this mutation with the clinical phenotype was confirmed in the family.⁵⁷ The finding was supported by two genome-wide association studies, which identified SNP (rs3858145, $p=3.4\times 10^{-10}$) and SNP (rs1900004, $p=2.67\times 10^{-33}$) within 20 kb and 10 kb of *ATOH7*, respectively.^{58,59} However, pathogenic *ATOH7* variants were not discovered in an investigation of 34 patients with ONH⁶⁰ and 76 other patients with microphthalmia/anophthalmia/coloboma.⁶¹ Homozygous knockout *Atoh7*^{-/-} mice are viable and fertile, and appear normal externally. Although they tend to have normal-sized eyes, there is an 80%–95% reduction in the number of retinal ganglion cells, with very thin or absent optic nerves.^{56,62}

Chromatin remodelling

KANSL1 (17q21.31 microdeletion)

KAT8 regulatory NSL complex subunit 1 (*KANSL1*) encodes a nuclear protein that is a key component of a histone acetyltransferase complex.⁶³ *KANSL1* is one of the five known protein-coding genes in the 17q21.31 microdeletion syndrome locus (MIM 610443). It was later found that haploinsufficiency of *KANSL1* was sufficient to cause the phenotypes of 17q21.31 microdeletion syndrome, also known as Koolen-de Vries syndrome (KdVS).⁶⁴ KdVS is a multisystem disorder, characterised by developmental delay/intellectual disability, hypotonia and characteristic facial dysmorphism. Additional features include overly social and friendly behaviour, epilepsy, congenital heart defects, urogenital malformations, musculoskeletal anomalies and ectodermal anomalies. Zollino *et al* reported a deletion patient (patient 28) with hypoplastic ocular globe, unilateral ONH, strabismus, hearing impairment and craniosynostosis.⁶⁵ Koolen *et al* reported another deletion patient (case 32) with ONH, hypermetropia, strabismus, esotropia and corpus callosum abnormality.⁶⁶ The third deletion patient reported manifested cataracts, optic atrophy, hearing impairment and a small hippocampus.⁶⁷ Currently no mouse model for *Kansl1* deletion exists. Knockout of *wah* (*KANSL1* orthologue in *Drosophila*) is embryonal lethal in flies. Tissue-specific knockdown of *wah* in muscles and mushroom bodies (the learning and memory centres in *Drosophila* brains) leads to neuromuscular-junction defects and decreased learning ability.^{64,68} The function of *wah* in eye development is unknown currently.

α -Dystroglycan glycosylation

B3GALNT2

Beta-1,3-N-Acetylgalactosaminyltransferase 2 (*B3GALNT2*) encodes a glycosyltransferase that helps synthesise α -dystroglycan, which is an integral component of the dystrophin glycoprotein complex. Defects in glycosylation reduce the binding ability of α -dystroglycan to extracellular matrix ligands, causing a dystroglycanopathy. Stevens *et al* reported seven individuals with congenital muscular dystrophy-dystroglycanopathy, and a phenotype defined as ‘brain and eye anomalies type A11’ (MDDGA11, MIM 615181). These individuals carried either homozygous or compound heterozygous mutations in *B3GALNT2*. Two of the affected individuals had ONH. Currently, there is no murine model for *B3galnt2* loss-of-function studies; however, knockdown of *b3galnt2* in zebrafish showed retinal degeneration, impaired motility and brain abnormalities.⁶⁹

ISPD

Isoprenoid synthase domain-containing protein (*ISPD*) encodes a protein that is required for proper α -dystroglycan modification. Similar to *B3GALNT2*, *ISPD* mutations were identified in patients diagnosed with congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies, in this case type A7 (MDDGA7, MIM 614643). Willer *et al* reported seven individuals, including a pair of siblings, carrying homozygous or compound heterozygous mutations in *ISPD*. Two of the seven patients had ONH. One of the affected siblings was diagnosed with bilateral ONH, and the other had bilateral microphthalmia (status of optic nerves not mentioned in the study).⁷⁰ Roscioli *et al* identified two individuals with MDDGA7, one with a homozygous and the other with compound heterozygous mutations in *ISPD*. However, instead of being described with ONH, they were diagnosed with optic atrophy.⁷¹ The four individuals also shared brain malformations, including hydrocephalus, cerebellar hypoplasia and cobblestone lissencephaly. In a forward genetic screen for axon guidance defects in mice, it was found that homozygous loss-of-function *Ispl*^{L79*/L79*} (leucine to premature stop codon) leads to neonatal lethality, abnormal axon guidance in the hindbrain and abnormal fasciculation of the funiculus of the spinal cord. However, eye-related phenotypes were not reported in that mouse study.⁷²

Cytoskeleton and scaffolding protein

TUBA8

Tubulin alpha 8 (*TUBA8*) encodes a member of the α -tubulin protein family. α -Tubulins and β -tubulins heterodimerise and then assemble to form microtubules. Abdollahi *et al*⁷³ reported homozygous indel in an intron of *TUBA8* in three affected members of a consanguineous Pakistani family. The same homozygous deletion was found in an affected child from a second Pakistani family. The 14 bp deletion lies 11 bp upstream of the exon 2 splice junction. The deletion was predicted to interfere with correct splicing, which was verified by the reverse transcription PCR of lymphoblastoid cell line RNA from the patient. All four affected children have ONH with polymicrogyria, seizures, thin or absent corpus callosum and brainstem abnormalities. Surprisingly, expression of *Tuba8* is relatively low in developing mouse and human brains, even though the clinical phenotypes mainly present as brain malformations.⁷⁴ Currently, no mouse model exists for *Tuba8* mutations.

CASK

Calcium/calmodulin-dependent serine protein kinase (*CASK*) encodes a member of the membrane-associated guanylate kinase (MAGUK) protein family, which consists of scaffolding proteins associated with intercellular junctions.⁷⁵ Heterozygous or hemizygous mutations in the X-linked *CASK* gene in patients lead to microcephaly with pontine and cerebellar hypoplasia (MICPCH, MIM 300749).⁷⁶ The phenotypic spectrum of *CASK* mutations includes autistic traits, developmental delay/intellectual disability, axial hypotonia and/or peripheral hypertonia, movement and behavioural disorders, and seizures. Although ONH/optic atrophy is not fully expressed in patients with MICPCH, it has been reported in multiple studies.^{77,78} Other ophthalmological abnormalities include hyperopia, strabismus, astigmatism and nystagmus. Constitutive knockout mice (*Cask*^{-/-} and *Cask*^{-/-}) die within the first day after birth,⁷⁵ but deletion of a single *Cask* allele (*Cask*^{+/-}) in female mice has been found to recapitulate many human phenotypes, including microcephaly, hypotonia, ataxia and ONH without microphthalmia

or malformation of the brain midline.⁷⁹ The study suggested that Cask regulates oxidative metabolism in the brain, and the rate of glucose oxidation was reduced by 20% in the brain of *Cask*^{+/-} mice compared with wild-type littermates.⁷⁹

RNA splicing

PUF60

Poly(U) binding splicing factor 60 (*PUF60*) encodes a ribonucleoprotein-binding protein, which is involved in pre-mRNA splicing and transcriptional regulation. Dauber *et al*⁸⁰ identified the first patient with a de novo heterozygous variant, p.H169Y in *PUF60*. El Chehadeh *et al*⁸¹ reported another five patients with de novo heterozygous variants in *PUF60*. All six patients identified to date manifest the same facial gestalt as seen in individuals with 8q24.3 microdeletion syndrome, also known as Verheij syndrome (MIM 615583). Other shared clinical features include bilateral ONH (2/6), developmental delay (6/6), cardiac defects (5/6), short stature (5/6), joint laxity and/or dislocation (5/6), vertebral anomalies (3/6) and feeding difficulties (3/6). Currently, there is no mouse model for *Puf60* mutations.

MAPK signalling pathway

BRAF

B-Raf proto-oncogene (*BRAF*) encodes a serine/threonine-protein kinase that plays a role in regulating the MAP kinase signalling pathway. Mutations in *BRAF* are one of the causes of cardio-facio-cutaneous (CFC) syndrome (MIM 115150). Armour and Allanson reported 38 individuals with CFC, 32 of which had autosomal dominant variants in *BRAF*. The remaining six individuals carried either *MEK1* or *MEK2* variants. Among the patients with *BRAF* mutations, ONH/dysplasia was diagnosed in 9 out of the 20 individuals who had provided ophthalmological assessments for review. Meanwhile, two out of six individuals carrying *MEK1* or *MEK2* variants had such diagnoses.⁸² *MEK1*, *MEK2* and *BRAF* are integral parts of the MAP kinase pathway. Although the signs of CFC overlap substantially with Noonan syndrome, it was estimated that only 2% (3/139) of patients with Noonan syndrome had ONH.⁸³ As most *BRAF* mutations in CFC are predicted to be gain of function, multiple corresponding mouse models have been generated. *Braf*^{+/*N600E*} and *Braf*^{+/*L597V*} mouse models, both carrying an allele expressing constitutively active Braf protein, recapitulate certain patient phenotypes, including small body size, facial dysmorphism, cardiomegaly and eye abnormalities (cataracts).^{84 85}

Others

ALDH1A3

Aldehyde dehydrogenase one family member A3 (*ALDH1A3*) encodes an aldehyde dehydrogenase enzyme that uses retinal (retinaldehyde) as a substrate to synthesise retinoic acid, which plays a critical role in eye development.⁸⁶ Fares-Taie *et al*⁸⁷ identified two homozygous missense mutations (p.R89C and p.A493P) and one homozygous splice-site mutation in four individuals from three consanguineous families. These mutations segregated with microphthalmia/anophthalmia along with occasional orbital cystic, neurological and cardiac anomalies in the family. Available MRI data from two individuals showed hypoplastic optic nerves. Yahyavi *et al*⁸⁸ identified a homozygous nonsense mutation, p.L389*, which they predicted to cause nonsense-mediated decay, in a patient with microphthalmia/anophthalmia and hypoplasia of the optic nerve and optic chiasm. Homozygous knockout *Aldh1a3*^{-/-} mice are lethal perinatally and show defects in the invagination of the ventral optic cup, closure of

the choroid fissures and abnormal axonal projections of retinal cells into the brain.^{86 89} Interestingly, *Aldh1a3* is also critical for the development of nasal structures, and null mice die of respiratory distress at birth, resulting from choanal atresia (blockage of nasal passage). However, all the human patients reported to date do not display these nasal or choanal abnormalities, suggesting residual protein function of the pathogenic alleles, or species-dependent differences in mice versus humans.

DDHD2

DDHD domain-containing protein 2 (*DDHD2*) encodes a phospholipase enzyme and is a major brain triglyceride hydrolase. Schuurs-Hoeijmakers *et al*⁹⁰ reported five individuals diagnosed with complex hereditary spastic paraplegia (SPG54, MIM 615033) carrying biallelic mutations in *DDHD2*. Three out of five individuals had ONH. Other shared features included developmental delay/intellectual disability, hypotonia, strabismus and thin corpus callosum. *Ddhd2* constitutive knockout mice (*Ddhd2*^{-/-}) exhibit defects in movement and cognitive function, and show selective elevation in triacylglycerols through the CNS. However, the visual ability in these mice is not different substantially from wild-type controls in the optomotor test.⁹¹

DISCUSSION

Molecular network of transcription factors in eye development

Eye morphogenesis in vertebrates is an intricate multistep process, including the formation of the eye pit, optic vesicle, optic cup, lens and neurogenesis in the neural retina (NR) (figure 1). Many key transcription factors participate in these sequential events to ensure the proper formation and maturation of the eye.⁹² While most knowledge described here is derived from murine studies, a high level of conservation exists for the sequence and function of these key transcription factors in eye development between human and murine models, so the described processes carry significance in humans as well. In mice, the evagination of optic pits leads to the formation of the early optic vesicle at E9.5. Then, the invagination of optic vesicle at E10.5 results in the formation of a dual-layered optic cup, which consists of three main domains: the NR, retinal pigment epithelium and optic stalk (OS). The OS later becomes the optic nerve when the axons of the retinal ganglion cells fill the cavity of the stalk and complete the closure of the choroid fissure (figure 1).

The boundary between OS and NR is established at the optic disc, which serves an entrance for the blood vessels to the eye and as an exit for the axons of retinal ganglion cells from the eye. Pax6, an NR marker, and Pax2, a ventral OS marker, antagonise each other to establish the sharp boundary (figure 1).⁹³ Reciprocal expansion of Pax2 and Pax6 gene expressions is seen in the corresponding loss-of-function mutant mice. Disruption of this boundary causes defects in the optic nerve, OS, retina, lens and optic fissure closure.^{94 95} Vax1 and Vax2 are also involved in the boundary formation by inhibiting Pax6 expression, given that the expression of Pax6 and Pax2 is rapidly acquired and lost from the OS in Vax1 and Vax2 double knockouts at E10.⁹⁶

Another example of boundary formation defects is reported in *Nr2f1* and *Nr2f2* double knockout mice. Increased expression of Pax6 in NR and decreased expression of Pax2 in ventral OS, accompanied by reduced expression of Vax1 in the OS, shift the NR-vOS boundary proximally, eventually leading to abnormal differentiation of the OS.⁴⁰ These data suggested that *Nr2f1* and *Nr2f2* are the key regulators that balance the expression of Pax6 and Pax2 during the early development of the optic cup.




Figure 1 Eye development and key transcription factors. In early eye development, the evagination of optic pits leads to the formation of the early optic vesicle. The surface ectoderm and the underlying neuroepithelium invaginate to form the lens vesicle and bilayered optic cup, respectively. The outer layer of the optic cup gives rise to the retinal pigment epithelium, while the inner layer gives rise to the neural retina. The optic stalk later becomes the optic nerve when the axons of the retinal ganglion cells fill the cavity of the stalk and complete the closure of the choroid fissure. Many key transcription factors, mutations of which cause ONH, participate in the proper development of the optic stalk/optic nerve. ONH, optic nerve hypoplasia; RGC, retinal ganglion cell; RPE, retinal pigment epithelium.

However, the eye phenotypes in the individuals with heterozygous *PAX6* mutations are generally more severe than those with heterozygous *NR2F1* mutations. This could be explained by the functional redundancy between *NR2F1* and *NR2F2*, given that eye-specific double knockout of *Nr2f1* and *Nr2f2* in mice leads to major eye abnormalities but does not do so in eye-specific single knockout of *Nr2f1*.⁴⁰

Two transcription factors synergistically regulating lens development are *Pax6* and *Sox2*, again indicating the intricate interaction between transcription factors during eye development.⁹⁷ *Pax6* and *Sox2* form a co-DNA-binding complex, which activates cooperatively the lens-specific enhancer element DC5 in order to differentiate embryonic ectoderm into lens ectoderm. In contrast to the synergistic relationship, the same two transcription factors antagonise each other in the developing optic cup to specify the multipotent optic cup progenitors towards a neurogenic fate (*Sox2*) or a non-neurogenic fate (*Pax6*).⁹⁸ This suggests that the interplay between transcription factors may be highly cell-type specific and developmental stage specific during eye development.

Adding to the complexity of eye development is the fact that the aforementioned transcription factors are also involved in the morphogenesis of the forebrain and other brain regions, such as the midline brain, hypothalamus and pituitary gland. This involvement may explain why ONH is more commonly a part of a syndrome involving other structural brain anomalies, rather than an isolated finding. Similarly, most mutant mouse models manifest more extensive systemic defects, in addition to isolated ONH. To date, multiple genes are implicated in ONH; however, most of them are associated with other eye anomalies and/or brain structural defects. Nevertheless, the possibility that one single gene mutation leads to isolated ONH should not be discounted.

CONCLUSION

With ONH being the second most common cause of congenital visual impairment,¹⁰⁰ the investigation of the causes and risk factors of ONH is of great importance. Although previous

studies had mostly attributed ONH to the prenatal environment, the identification of an increasing number of genetic causes of ONH suggests multiple aetiological mechanisms, including gene–environment interactions, as well as monogenic causes with high penetrance. The consideration of gene–environment interactions and potential genetic modifiers is based, in part, on the presence of variable expressivity of related phenotypes among individuals carrying the same genetic variants.

Eye morphogenesis in mammalian species is an intricate process. Many key transcription factors relevant for eye development also play roles in the morphogenesis of forebrain. This interplay causes more complex clinical phenotypes, many of which involve cognitive deficits and behavioural alterations. With the advancement and clinical availability of genome-wide sequencing technology, we anticipate that more genes will be implicated in the aetiology of ONH. In some cases, the modes of inheritance may go well beyond Mendelian genetics, for example, digenic or oligogenic inheritance. These steps will lead to an increased molecular diagnostic rate for individuals with ONH per se. Additional research will investigate whether the functional consequences associated with the respective disorders are all due to structural deficits from altered neurodevelopment, or whether some function(s) could be regained, with therapeutic intervention, even started later in life.

Contributors CAC wrote the manuscript. JY created the figure. RAL edited the manuscript. CPS conceived and edited the manuscript.

Competing interests None declared.

Provenance and peer review Commissioned; externally peer reviewed.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Magnus H. Zur Karuistik der angeborenen Schnerven-milbildungen. *Klin Monbl Augenheilkd.* 1884;2:85-87.
- Briere W. Absence des papillères, cécité absolue. *Ann Ocul* 1877;78:41–2.
- Schwarz O. Ein fall von mangelhafter bildung (Hypoplasie) beider sehnerven. *Albrecht Von Graefes Arch Ophthalmol* 1915;90:326–8.

- 4 Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK. Childhood blindness. *J Aapos* 1999;3:26–32.
- 5 Ryabets-Lienhard A, Stewart C, Borchert M, Geffner ME. The optic nerve hypoplasia spectrum: review of the literature and clinical guidelines. *Adv Pediatr* 2016;63:127–46.
- 6 Garcia-Filion P, Borchert M. Optic nerve hypoplasia syndrome: a review of the epidemiology and clinical associations. *Curr Treat Options Neurol* 2013;15:78–89.
- 7 Cidis MB, Warshowsky JH, Goldrich SG, Meltzer CC. Mirror-image optic nerve dysplasia with associated anisometropia in identical twins. *J Am Optom Assoc* 1997;68:325–9.
- 8 Benner JD, Preslan MW, Gratz E, Joslyn J, Schwartz M, Kelman S. Septo-optic dysplasia in two siblings. *Am J Ophthalmol* 1990;109:632–7.
- 9 Ouvrier R, Billson F. Optic nerve hypoplasia: a review. *J Child Neurol* 1986;1:181–8.
- 10 Azuma N, Yamaguchi Y, Handa H, Tadokoro K, Asaka A, Kawase E, Yamada M. Mutations of the PAX6 gene detected in patients with a variety of optic-nerve malformations. *Am J Hum Genet* 2003;72:1565–70.
- 11 Kelberman D, Rizzoti K, Avilion A, Bitner-Grindzic M, Cianfarani S, Collins J, Chong WK, Kirk JM, Achermann JC, Ross R, Carmignac D, Lovell-Badge R, Robinson IC, Dattani MT. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. *J Clin Invest* 2006;116:2442–55.
- 12 Parr JR, Dale NJ, Shaffer LM, Salt AT. Social communication difficulties and autism spectrum disorder in young children with optic nerve hypoplasia and/or septo-optic dysplasia. *Dev Med Child Neurol* 2010;52:917–21.
- 13 Garcia-Filion P, Borchert M. Prenatal determinants of optic nerve hypoplasia: review of suggested correlates and future focus. *Surv Ophthalmol* 2013;58:610–9.
- 14 Martinez-Barbera JP, Rodriguez TA, Bedington RS. The homeobox gene *Hesx1* is required in the anterior neural ectoderm for normal forebrain formation. *Dev Biol* 2000;223:422–30.
- 15 Dattani MT, Martinez-Barbera JP, Thomas PQ, Brickman JM, Gupta R, Mårtensson IL, Toresson H, Fox M, Wales JK, Hindmarsh PC, Krauss S, Bedington RS, Robinson IC. Mutations in the homeobox gene *HESX1/Hesx1* associated with septo-optic dysplasia in human and mouse. *Nat Genet* 1998;19:125–33.
- 16 Wales JK, Quarrell OW. Evidence for possible mendelian inheritance of septo-optic dysplasia. *Acta Paediatr* 1996;85:391–2.
- 17 Tajima T, Hattori T, Nakajima T, Okuhara K, Sato K, Abe S, Nakae J, Fujieda K. Sporadic heterozygous frameshift mutation of *HESX1* causing pituitary and optic nerve hypoplasia and combined pituitary hormone deficiency in a Japanese patient. *J Clin Endocrinol Metab* 2003;88:45–50.
- 18 Cohen RN, Cohen LE, Botero D, Yu C, Sagar A, Jurkiewicz M, Radovick S. Enhanced repression by *HESX1* as a cause of hypopituitarism and septo-optic dysplasia. *J Clin Endocrinol Metab* 2003;88:4832–9.
- 19 Jordan T, Hanson I, Zaletayev D, Hodgson S, Prosser J, Seawright A, Hastie N, van Heyningen V. The human *PAX6* gene is mutated in two patients with aniridia. *Nat Genet* 1992;1:328–32.
- 20 Hingorani M, Williamson KA, Moore AT, van Heyningen V. Detailed ophthalmologic evaluation of 43 individuals with *PAX6* mutations. *Invest Ophthalmol Vis Sci* 2009;50:2581–90.
- 21 Paridaen JT, Huttner WB. Neurogenesis during development of the vertebrate central nervous system. *EMBO Rep* 2014;15:351–64.
- 22 Davis LK, Meyer KJ, Rudd DS, Librant AL, Epping EA, Sheffield VC, Wassink TH. *Pax6* 3' deletion results in aniridia, autism and mental retardation. *Hum Genet* 2008;123:371–8.
- 23 Hill RE, Favor J, Hogan BL, Ton CC, Saunders GF, Hanson IM, Prosser J, Jordan T, Hastie ND, van Heyningen V. Mouse small eye results from mutations in a paired-like homeobox-containing gene. *Nature* 1991;354:522–5.
- 24 Stoykova A, Fritsch R, Walther C, Gruss P. Forebrain patterning defects in small eye mutant mice. *Development* 1996;122:3453–65.
- 25 van der Meer-de Jong R, Dickinson ME, Woychik RP, Stubbs L, Hetherington C, Hogan BL. Location of the gene involving the small eye mutation on mouse chromosome 2 suggests homology with human aniridia 2 (AN2). *Genomics* 1990;7:270–5.
- 26 Dangata YY, Findlater GS, Dhillon B, Kaufman MH. Morphometric study of the optic nerve of adult normal mice and mice heterozygous for the small eye mutation (*Sey*⁺). *J Anat* 1994;185:627–35.
- 27 Matsuo T, Osumi-Yamashita N, Noji S, Ohuchi H, Koyama E, Myokai F, Matsuo N, Taniguchi S, Doi H, Iseki S. A mutation in the *Pax-6* gene in rat small eye is associated with impaired migration of midbrain crest cells. *Nat Genet* 1993;3:299–304.
- 28 Umeda T, Takashima N, Nakagawa R, Maekawa M, Ikegami S, Yoshikawa T, Kobayashi K, Okanoya K, Inokuchi K, Osumi N. Evaluation of *Pax6* mutant rat as a model for autism. *PLoS One* 2010;5:e15500.
- 29 Haubst N, Berger J, Radjendirane V, Graw J, Favor J, Saunders GF, Stoykova A, Götz M. Molecular dissection of *Pax6* function: the specific roles of the paired domain and homeodomain in brain development. *Development* 2004;131:6131–40.
- 30 Walcher T, Xie Q, Sun J, Irmeler M, Beckers J, Öztürk T, Niessing D, Stoykova A, Cvekl A, Ninkovic J, Götz M. Functional dissection of the paired domain of *Pax6* reveals molecular mechanisms of coordinating neurogenesis and proliferation. *Development* 2013;140:1123–36.
- 31 Taranova OV, Magness ST, Fagan BM, Wu Y, Surzenko N, Hutton SR, Pevny LH. *SOX2* is a dose-dependent regulator of retinal neural progenitor competence. *Genes Dev* 2006;20:1187–202.
- 32 Fantes J, Ragge NK, Lynch SA, McGill NI, Collin JR, Howard-Peebles PN, Hayward C, Vivian AJ, Williamson K, van Heyningen V, FitzPatrick DR. Mutations in *SOX2* cause anophthalmia. *Nat Genet* 2003;33:461–3.
- 33 Bakrania P, Robinson DO, Bunyan DJ, Salt A, Martin A, Crolla JA, Wyatt A, Fielder A, Ainsworth J, Moore A, Read S, Uddin J, Laws D, Pascuel-Salcedo D, Ayuso C, Allen L, Collin JR, Ragge NK. *SOX2* anophthalmia syndrome: 12 new cases demonstrating broader phenotype and high frequency of large gene deletions. *Br J Ophthalmol* 2007;91:1471–6.
- 34 Gerth-Kahlert C, Williamson K, Ansari M, Rainger JK, Hingst V, Zimmermann T, Tech S, Guthoff RF, van Heyningen V, Fitzpatrick DR. Clinical and mutation analysis of 51 probands with anophthalmia and/or severe microphthalmia from a single center. *Mol Genet Genomic Med* 2013;1:15–31.
- 35 Zhou J, Kherani F, Bardakjian TM, Katowitz J, Hughes N, Schimmenti LA, Schneider A, Young TL. Identification of novel mutations and sequence variants in the *SOX2* and *CHX10* genes in patients with anophthalmia/microphthalmia. *Mol Vis* 2008;14:583–92.
- 36 Ragge NK, Lorenz B, Schneider A, Bushby K, de Sanctis L, de Sanctis U, Salt A, Collin JR, Vivian AJ, Free SL, Thompson P, Williamson KA, Sisodiya SM, Heyningen van V, Fitzpatrick DR. *SOX2* anophthalmia syndrome. *Am J Med Genet* 2005;135:1–7.
- 37 Jayakody SA, Andoniadou CL, Gaston-Massuet C, Signore M, Cariboni A, Bouloux PM, Le Tissier P, Pevny LH, Dattani MT, Martinez-Barbera JP. *SOX2* regulates the hypothalamo-pituitary axis at multiple levels. *J Clin Invest* 2012;122:3635–46.
- 38 Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on *SOX2* function. *Genes Dev* 2003;17:126–40.
- 39 Bosch DG, Boonstra FN, Gonzaga-Jauregui C, Xu M, de Ligjt J, Jhangiani S, Wiszniewski W, Muzny DM, Yntema HG, Pfundt R, Vissers LE, Spruijt L, Blokland EA, Chen CA, Lewis RA, Tsai SY, Gibbs RA, Tsai MJ, Lupski JR, Zoghbi HY, Cremers FP, de Vries BB, Schaaf CP. *NR2F1* mutations cause optic atrophy with intellectual disability. *Am J Hum Genet* 2014;94:303–9.
- 40 Tang K, Xie X, Park JJ, Jamrich M, Tsai S, Tsai MJ. COUP-TFs regulate eye development by controlling factors essential for optic vesicle morphogenesis. *Development* 2010;137:725–34.
- 41 Brown KK, Alkuraya FS, Matos M, Robertson RL, Kimonis VE, Morton CC. *NR2F1* deletion in a patient with a de novo paracentric inversion, inv(5)(q15q33.2), and syndromic deafness. *American journal of medical genetics Part A* 2009;149A:931–8.
- 42 Al-Kateb H, Shimony JS, Vineyard M, Manwaring L, Kulkarni S, Shinawi M. *NR2F1* haploinsufficiency is associated with optic atrophy, dysmorphism and global developmental delay. *Am J Hum Genet* 2013;161A:377–81.
- 43 Chen CA, Bosch DG, Cho MT, Rosenfeld JA, Shinawi M, Lewis RA, Mann J, Jayakar P, Payne K, Walsh L, Moss T, Schreiber A, Schoonveld C, Monaghan KG, Elmslie F, Douglas G, Boonstra FN, Millan F, Cremers FP, McKnight D, Richard G, Juusola J, Kendall F, Ramsey K, Anyane-Yeboah K, Malkin E, Chung WK, Niyazov D, Pascual JM, Walkiewicz M, Veluchamy V, Li C, Hisama FM, de Vries BB, Schaaf C. The expanding clinical phenotype of Bosch-Boonstra-Schaaf optic atrophy syndrome: 20 new cases and possible genotype-phenotype correlations. *Genet Med* 2016;18:1143–50.
- 44 Cooney AJ, Tsai SY, O'Malley BW, Tsai MJ. Chicken ovalbumin upstream promoter transcription factor (COUP-TF) dimers bind to different GGTC A response elements, allowing COUP-TF to repress hormonal induction of the vitamin D₃ thyroid hormone, and retinoic acid receptors. *Mol Cell Biol* 1992;12:4153–63.
- 45 Qiu Y, Pereira FA, DeMayo FJ, Lydon JP, Tsai SY, Tsai MJ. Null mutation of mCOUP-TF results in defects in morphogenesis of the glossopharyngeal ganglion, axonal projection, and arborization. *Genes Dev* 1997;11:1925–37.
- 46 Armentano M, Filosa A, Andolfi G, Studer M. COUP-TFI is required for the formation of commissural projections in the forebrain by regulating axonal growth. *Development* 2006;133:4151–62.
- 47 Acampora D, Mazan S, Lallemand Y, Avantaggiato V, Maury M, Simeone A, Brûlet P. Forebrain and midbrain regions are deleted in *Otx2^{fl}* mutants due to a defective anterior neuroectoderm specification during gastrulation. *Development* 1995;121:3279–90.
- 48 Wyatt A, Bakrania P, Bunyan DJ, Osborne RJ, Crolla JA, Salt A, Ayuso C, Newbury-Ecob R, Abou-Rayyah Y, Collin JR, Robinson D, Ragge N. Novel heterozygous *OTX2* mutations and whole gene deletions in anophthalmia, microphthalmia and coloboma. *Hum Mutat* 2008;29:E278–83.
- 49 Schilter KF, Schneider A, Bardakjian T, Soucy JF, Tyler RC, Reis LM, Semina EV. *OTX2* microphthalmia syndrome: four novel mutations and delineation of a phenotype. *Clin Genet* 2011;79:158–68.
- 50 Ragge NK, Brown AG, Poloschek CM, Lorenz B, Henderson RA, Clarke MP, Russell-Eggitt I, Fielder A, Gerrelli D, Martinez-Barbera JP, Ruddle P, Hurst J, Collin JR, Salt A, Cooper ST, Thompson PJ, Sisodiya SM, Williamson KA, Fitzpatrick DR, van Heyningen V, Hanson IM. Heterozygous mutations of *OTX2* cause severe ocular malformations. *Am J Hum Genet* 2005;76:1008–22.
- 51 Ashkenazi-Hoffnung L, Leberthal Y, Wyatt AW, Ragge NK, Dateki S, Fukami M, Ogata T, Phillip M, Gat-Yablonski G. A novel loss-of-function mutation in *OTX2* in

- a patient with anophthalmia and isolated growth hormone deficiency. *Hum Genet* 2010;127:721–9.
- 52 Matsuo I, Kuratani S, Kimura C, Takeda N, Aizawa S. Mouse Otx2 functions in the formation and patterning of rostral head. *Genes Dev* 1995;9:2646–58.
- 53 Hallonet M, Hollemann T, Pieler T, Gruss P. Vax1, a novel homeobox-containing gene, directs development of the basal forebrain and visual system. *Genes Dev* 1999;13:3106–14.
- 54 Slavotinek AM, Chao R, Vacik T, Yahyavi M, Abouzeid H, Bardakjian T, Schneider A, Shaw G, Sherr EH, Lemke G, Youssef M, Schorderet DF. VAX1 mutation associated with microphthalmia, corpus callosum agenesis, and orofacial clefting: the first description of a VAX1 phenotype in humans. *Hum Mutat* 2012;33:364–8.
- 55 Hoffmann HM, Tamrazian A, Xie H, Pérez-Millán MI, Kauffman AS, Mellon PL. Heterozygous deletion of ventral anterior homeobox (vax1) causes subfertility in mice. *Endocrinology* 2014;155:4043–53.
- 56 Brown NL, Patel S, Brzezinski J, Glaser T. Math5 is required for retinal ganglion cell and optic nerve formation. *Development* 2001;128:2497–508.
- 57 Khan K, Logan CV, McKibbin M, Sheridan E, Elcioglu NH, Yenice O, Parry DA, Fernandez-Fuentes N, Abdelhamed ZI, Al-Maskari A, Poulter JA, Mohamed MD, Carr IM, Morgan JE, Jafri H, Raashid Y, Taylor GR, Johnson CA, Inglehearn CF, Toomes C, Ali M. Next generation sequencing identifies mutations in atonal homolog 7 (ATOH7) in families with global eye developmental defects. *Hum Mol Genet* 2012;21:776–83.
- 58 Macgregor S, Hewitt AW, Hysi PG, Ruddle JB, Medland SE, Henders AK, Gordon SD, Andrew T, McEvoy B, Sanfilippo PG, Carbonaro F, Tah V, Li YJ, Bennett SL, Craig JE, Montgomery GW, Tran-Viet KN, Brown NL, Spector TD, Martin NG, Young TL, Hammond CJ, Mackey DA. Genome-wide association identifies ATOH7 as a major gene determining human optic disc size. *Hum Mol Genet* 2010;19:2716–24.
- 59 Ramdas WD, van Koolwijk LM, Ikram MK, Jansonius NM, de Jong PT, Bergen AA, Isaacs A, Amin N, Aulchenko YS, Wolfs RC, Hofman A, Rivadeneira F, Oostra BA, Uitterlinden AG, Hysi P, Hammond CJ, Lemij HG, Vingerling JR, Klaver CC, van Duijn CM. A genome-wide association study of optic disc parameters. *PLoS Genet* 2010;6:e1000978.
- 60 Lim SH, St Germain E, Tran-Viet KN, Staffieri S, Marino M, Dollfus PH, Nading EB, Crowe S, Gole G, Perdomo-Trujillo Y, Haybittel M, Elder J, Pelletier V, Traboulsi E, Mackey D, Young TL. Sequencing analysis of the ATOH7 gene in individuals with optic nerve hypoplasia. *Ophthalmic Genet* 2014;35:1–6.
- 61 Garcia-Montalvo IA, Pelcastre-Luna E, Nelson-Mora J, Buentello-Volante B, Miranda-Duarte A, Zenteno JC. Mutational screening of FOXE3, GDF3, ATOH7, and ALDH1A3 in congenital ocular malformations. Possible contribution of the FOXE3 p.VAL201MET variant to the risk of severe eye malformations. *Ophthalmic Genet* 2014;35:190–2.
- 62 Wang SW, Kim BS, Ding K, Wang H, Sun D, Johnson RL, Klein WH, Gan L. Requirement for math5 in the development of retinal ganglion cells. *Genes Dev* 2001;15:24–9.
- 63 Dias J, Van Nguyen N, Georgiev P, Gaub A, Bretschneider J, Cusack S, Kadlec J, Akhtar A. Structural analysis of the KANSL1/WDR5/KANSL2 complex reveals that WDR5 is required for efficient assembly and chromatin targeting of the NSL complex. *Genes Dev* 2014;28:929–42.
- 64 Koolen DA, Kramer JM, Neveling K, Nillesen WM, Moore-Barton HL, Elmslie FV, Toutain A, Amiel J, Malan V, Tsai AC, Cheung SW, Gilissen C, Verwiel ET, Martens S, Feuth T, Bongers EM, de Vries P, Scheffer H, Vissers LE, de Brouwer AP, Brunner HG, Veltman JA, Schenck A, Yntema HG, de Vries BB. Mutations in the chromatin modifier gene KANSL1 cause the 17q21.31 microdeletion syndrome. *Nat Genet* 2012;44:639–41.
- 65 Zollino M, Marangi G, Ponzi E, Orteschi D, Ricciardi S, Lattante S, Murdolo M, Battaglia D, Contaldo I, Mercuri E, Stefanini MC, Caumes R, Ederly P, Rossi M, Piccione M, Corsello G, Della Monica M, Scarano F, Priolo M, Gentile M, Zampino G, Vijzelaar R, Abdulrahman O, Rauch A, Oneda B, Deardorff MA, Saitta SC, Falk MJ, Dubbs H, Zackai E. Intragenic KANSL1 mutations and chromosome 17q21.31 deletions: broadening the clinical spectrum and genotype-phenotype correlations in a large cohort of patients. *J Med Genet* 2015;52:804–14.
- 66 Koolen DA, Pfundt R, Linda K, Beunders G, Veenstra-Knol HE, Conta JH, Fortuna AM, Gillissen-Kaesbach G, Dugan S, Halbach S, Abdul-Rahman OA, Winesett HM, Chung WK, Dalton M, Dimova PS, Mattina T, Prescott K, Zhang HZ, Saal HM, Hehir-Kwa JY, Willemsen MH, Ockeloen CW, Jongmans MC, Van der Aa N, Failla P, Barone C, Avola E, Brooks AS, Kant SG, Gerkes EH, Firth HV, Öunap K, Bird LM, Masser-Frye D, Friedman JR, Sokunbi MA, Dixit A, Splitt M, Kukulich MK, McGaughran J, Coe BP, Flórez J, Nadif Kasri N, Brunner HG, Thompson EM, Geetz J, Romano C, Eichler EE, de Vries BB. The Koolen-de Vries syndrome: a phenotypic comparison of patients with a 17q21.31 microdeletion versus a KANSL1 sequence variant. *Eur J Hum Genet* 2016;24:652–9.
- 67 Wright EB, Donnai D, Johnson D, Clayton-Smith J. Cutaneous features in 17q21.31 deletion syndrome: a differential diagnosis for cardio-facio-cutaneous syndrome. *Clin Dysmorphol* 2011;20:15–20.
- 68 Lone M, Kungl T, Koper A, Bottenberg W, Kammerer R, Klein M, Sweeney ST, Auburn RP, O’Kane CJ, Prokop A. The nuclear protein Waharan is required for endosomal-lysosomal trafficking in Drosophila. *J Cell Sci* 2010;123:2369–74.
- 69 Stevens E, Carss KJ, Cirak S, Foley AR, Torelli S, Willer T, Tambunan DE, Yau S, Brodd L, Sewry CA, Feng L, Haliloglu G, Orhan D, Dobyns WB, Enns GM, Manning M, Krause A, Salih MA, Walsh CA, Hurler M, Campbell KP, Manzini MC, Stemple D, Lin YY, Muntoni F. Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of adystroglycan. *Am J Hum Genet* 2013;92:354–65.
- 70 Willer T, Lee H, Lommel M, Yoshida-Moriguchi T, de Bernabe DB, Venke D, Cirak S, Schachter H, Vajsar J, Voit T, Muntoni F, Loder AS, Dobyns WB, Winder TL, Strahl S, Mathews KD, Nelson SF, Moore SA, Campbell KP. ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. *Nat Genet* 2012;44:575–80.
- 71 Roscioli T, Kamsteeg EJ, Buysse K, Maystadt I, van Reeuwijk J, van den Elzen C, van Beusekom E, Riemersma M, Pfundt R, Vissers LE, Schraders M, Altunoglu U, Buckley MF, Brunner HG, Grisart B, Zhou H, Veltman JA, Gilissen C, Mancini G, Delrée P, Willemsen MA, Ramadza DP, Chitayat D, Bennett C, Sheridan E, Peeters EA, Tan-Sindhunata GM, de Die-Smulders CE, Devriendt K, Kayserli H, El-Hashash OA, Stemple DL, Lefeber DJ, Lin YY, van Bokhoven H. Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of adystroglycan. *Nat Genet* 2012;44:581–5.
- 72 Wright KM, Lyon KA, Leung H, Leahy DJ, Ma L, Ginty DD. Dystroglycan organizes axon guidance cue localization and axonal pathfinding. *Neuron* 2012;76:931–44.
- 73 Abdollahi MR, Morrison E, Sirey T, Molnar Z, Hayward BE, Carr IM, Springell K, Woods CG, Ahmed M, Hattin L, Corry P, Pilz DT, Stoodley N, Crow Y, Taylor GR, Bonthron DT, Sheridan E. Mutation of the variant alpha-tubulin TUBA8 results in polymicrogyria with optic nerve hypoplasia. *Am J Hum Genet* 2009;85:737–44.
- 74 Braun A, Breuss M, Salzer MC, Flint J, Cowan NJ, Keays DA. Tuba8 is expressed at low levels in the developing mouse and human brain. *Am J Hum Genet* 2010;86:819–22.
- 75 Atasoy D, Schoch S, Ho A, Nadasy KA, Liu X, Zhang W, Mukherjee K, Nosyreva ED, Fernandez-Chacon R, Missler M, Kavali ET, Südhof TC. Deletion of CASK in mice is lethal and impairs synaptic function. *Proc Natl Acad Sci U S A* 2007;104:2525–30.
- 76 Najm J, Horn D, Wimplinger I, Golden JA, Chizhikov VV, Sudi J, Christian SL, Ullmann R, Kuechler A, Haas CA, Flubacher A, Charnas LR, Uyanik G, Frank U, Klopocki E, Dobyns WB, Kutsche K. Mutations of CASK cause an X-linked brain malformation phenotype with microcephaly and hypoplasia of the brainstem and cerebellum. *Nat Genet* 2008;40:1065–7.
- 77 Moog U, Bierhals T, Brand K, Bautsch J, Biskup S, Brune T, Denecke J, de Die-Smulders CE, Evers C, Hempel M, Henneke M, Yntema H, Menten B, Pietz J, Pfundt R, Schmidtke J, Steinemann D, Stumpel CT, Van Maldergem L, Kutsche K. Phenotypic and molecular insights into CASK-related disorders in males. *Orphanet J Rare Dis* 2015;10:44.
- 78 Moog U, Kutsche K, Kortüm F, Chilian B, Bierhals T, Apehshiotis N, Balg S, Chassaing N, Coubes C, Das S, Engels H, Van Esch H, Grasshoff U, Heise M, Isidor B, Jarvis J, Koehler U, Martin T, Oehl-Jaschkowitz B, Ortibus E, Pilz DT, Prabhakar P, Rappold G, Rau I, Rettenberger G, Schlüter G, Scott RH, Shoukier M, Wohlleber E, Zirn B, Dobyns WB, Uyanik G. Phenotypic spectrum associated with CASK loss-of-function mutations. *J Med Genet* 2011;48:741–51.
- 79 Srivastava S, McMillan R, Willis J, Clark H, Chavan V, Liang C, Zhang H, Hulver M, Mukherjee K. X-linked intellectual disability gene CASK regulates postnatal brain growth in a non-cell autonomous manner. *Acta Neuropathol Commun* 2016;4:30.
- 80 Dauber A, Golzio C, Guenet C, Jodelka FM, Kibek M, Kjaergaard S, Leheup B, Martinet D, Nowaczyk MJ, Rosenfeld JA, Zeeman S, Zunich J, Beckmann JS, Hirschhorn JN, Hastings ML, Jacquemont S, Katsanis N. SCRIB and PUF60 are primary drivers of the multisystemic phenotypes of the 8q24.3 copy-number variant. *Am J Hum Genet* 2013;93:798–811.
- 81 El Chehadeh S, Kerstjens-Frederikse WS, Thevenon J, Kuentz P, Bruel AL, Thauvin-Robinet C, Besignor C, Dollfus H, Laugel V, Rivière JB, Duffourd Y, Bonnet C, Robert MP, Isaïko R, Straub M, Creuzot-Garcher C, Calvas P, Chassaing N, Loëys B, Reyniers E, Vandeweyer G, Kooy F, Hancárová M, Havlovicová M, Prchalová D, Sedláček Z, Gilissen C, Pfundt R, Wassink-Ruiter JS, Faivre L. Dominant variants in the splicing factor PUF60 cause a recognizable syndrome with intellectual disability, heart defects and short stature. *Eur J Hum Genet* 2016;25:43–51.
- 82 Armour CM, Allanson JE. Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. *J Med Genet* 2008;45:249–54.
- 83 van Trier DC, Vos AM, Draaijer RW, van der Burgt I, Draaisma JM, Cruysberg JR. Ocular manifestations of noonan syndrome: a prospective clinical and genetic study of 25 patients. *Ophthalmology* 2016;123:2137–46.
- 84 Urošević J, Sauzeau V, Soto-Montenegro ML, Reig S, Desco M, Wright EM, Cañamero M, Mulero F, Ortega S, Bustelo XR, Barbacid M. Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. *Proc Natl Acad Sci U S A* 2011;108:5015–20.
- 85 Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, Mercer K, Kamata T, Lee P, Williams A, McMahon M, Marais R, Pritchard C. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. *Genes Dev* 2012;26:1945–58.
- 86 Dupé V, Matt N, Garnier JM, Chambon P, Mark M, Ghyselinck NB. A newborn lethal defect due to inactivation of retinaldehyde dehydrogenase type 3 is prevented by maternal retinoic acid treatment. *Proc Natl Acad Sci U S A* 2003;100:14036–41.

- 87 Fares-Taie L, Gerber S, Chassaing N, Clayton-Smith J, Hanein S, Silva E, Serey M, Serre V, Gérard X, Baumann C, Plessis G, Demeer B, Brétilion L, Bole C, Nitschke P, Munnich A, Lyonnet S, Calvas P, Kaplan J, Ragge N, Rozet JM. ALDH1A3 mutations cause recessive anophthalmia and microphthalmia. *Am J Hum Genet* 2013;92:265–70.
- 88 Yahyavi M, Abouzeid H, Gawdat G, de Preux AS, Xiao T, Bardakjian T, Schneider A, Choi A, Jorgenson E, Baier H, El Sada M, Schorderet DF, Slavotinek AM. ALDH1A3 loss of function causes bilateral anophthalmia/microphthalmia and hypoplasia of the optic nerve and optic chiasm. *Hum Mol Genet* 2013;22:3250–8.
- 89 Molotkov A, Molotkova N, Duester G. Retinoic acid guides eye morphogenetic movements via paracrine signaling but is unnecessary for retinal dorsoventral patterning. *Development* 2006;133:1901–10.
- 90 Schuurs-Hoeijmakers JH, Geraghty MT, Kamsteeg EJ, Ben-Salem S, de Bot ST, Nijhof B, van de Vondervoort Vondervoort, van der Graaf M, Nobau AC, Otte-Höller I, Vermeer S, Smith AC, Humphreys P, Schwartzentruber J, Ali BR, Al-Yahyaee SA, Tariq S, Pramathan T, Bayoumi R, Kremer HP, van de Warrenburg BP, van den Akker WM, Gilissen C, Veltman JA, Janssen IM, Vulto-van Silfhout AT, van der Velde-Visser S, Lefeber DJ, Diekstra A, Erasmus CE, Willemsen MA, Vissers LE, Lammens M, van Bokhoven H, Brunner HG, Wevers RA, Schenck A, Al-Gazali L, de Vries BB, de Brouwer AP. FORGE Canada Consortium. Mutations in DDHD2, encoding an intracellular phospholipase A(1), cause a recessive form of complex hereditary spastic paraplegia. *Am J Hum Genet* 2012;91:1073–81.
- 91 Inloes JM, Hsu KL, Dix MM, Viader A, Masuda K, Takei T, Wood MR, Cravatt BF. The hereditary spastic paraplegia-related enzyme DDHD2 is a principal brain triglyceride lipase. *Proc Natl Acad Sci U S A* 2014;111:14924–9.
- 92 Chow RL, Lang RA. Early eye development in vertebrates. *Annu Rev Cell Dev Biol* 2001;17:255–96.
- 93 Schwarz M, Ceconi F, Bernier G, Andrejewski N, Kammandel B, Wagner M, Gruss P. Spatial specification of mammalian eye territories by reciprocal transcriptional repression of Pax2 and Pax6. *Development* 2000;127:4325–34.
- 94 Klimova L, Kozmik Z. Stage-dependent requirement of neuroretinal Pax6 for lens and retina development. *Development* 2014;141:1292–302.
- 95 Torres M, Gómez-Pardo E, Gruss P. Pax2 contributes to inner ear patterning and optic nerve trajectory. *Development* 1996;122:3381–91.
- 96 Mui SH, Kim JW, Lemke G, Bertuzzi S. Vax genes ventralize the embryonic eye. *Genes Dev* 2005;19:1249–59.
- 97 Inoue M, Kamachi Y, Matsunami H, Imada K, Uchikawa M, Kondoh H. PAX6 and SOX2-dependent regulation of the Sox2 enhancer N-3 involved in embryonic visual system development. *Genes Cells* 2007;12:1049–61.
- 98 Kamachi Y, Uchikawa M, Tanouchi A, Sekido R, Kondoh H. Pax6 and SOX2 form a co-DNA-binding partner complex that regulates initiation of lens development. *Genes Dev* 2001;15:1272–86.
- 99 Matsushima D, Heavner W, Pevny LH. Combinatorial regulation of optic cup progenitor cell fate by SOX2 and PAX6. *Development* 2011;138:443–54.
- 100 Kong L, Fry M, Al-Samarraie M, Gilbert C, Steinkuller PG. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. *J Aapos* 2012;16:501–7.